What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2021-11-15 compared with 2021-08-16 · 17 added, 19 removed, 11 unchanged (77% of the section changed)

OTHER INFORMATION

Master Development and License Agreement for Products Between Elite Pharmaceuticals, Inc.

and Mikah Pharma LLC, effective as of June 10, 2021.(Portions of this Agreement have been redacted in compliance with Regulation S-K Item 601(b)(10)).*

Certification of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*

Certification of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*

Certification of Chief Executive Officer pursuant to 18 U.S.C.

Certification

of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*

Certification

of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*

Certification

of Chief Executive Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

Certification of Chief Financial Officer pursuant to 18 U.S.C.

Certification

of Chief Financial Officer pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*

5 unchanged sentences

XBRL Taxonomy Extension Presentation Linkbase Document

Page Interactive Data File (embedded within the Inline XBRL document)

Filed herewith.

Furnished herewith.

Pursuant to the requirements of

the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto

duly authorized.

ELITE PHARMACEUTICALS, INC.

August 16, 2021

/s/ Nasrat Hakim

Chief Executive Officer, President and

Chairman of the Board of Directors

(Principal Executive Officer)

August 16, 2021

/s/ Marc Bregman

Chief Financial Officer, Treasurer and Secretary

(Principal Financial and Accounting Officer)

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned thereunto duly authorized.

PHARMACEUTICALS, INC.

Executive Officer, President and

of the Board of Directors

Executive Officer)

Financial Officer, Treasurer and Secretary

Financial and Accounting Officer)

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information